Immune checkpoint inhibitors (ICIs) have shown promise in treating cancer patients and Pembrolizumab is a monoclonal IgG4 antibody that targets a human cell surface protein (receptor) called PD-1. Among the side effects a rare cranial nerve palsy unrelated to the surgical treatment may occur. We report a case of a woman, which after neurosurgical treatment for cerebellar metastasis presented painless third cranial nerve palsy. Informed consent was obtained from the patient for the publication of this report.
Third Cranial Nerve Palsy after Monoclonal Antibody Therapy for Lung Cancer: A Case Report / Missori, Paolo; Ambrosone, Angela; Cristofani, Leonardo; Fattapposta, Francesco; Curra', Antonio. - In: CASE REPORTS IN OPHTHALMOLOGY. - ISSN 1663-2699. - (2022), pp. 282-285. [10.1159/000524114]
Third Cranial Nerve Palsy after Monoclonal Antibody Therapy for Lung Cancer: A Case Report
Paolo Missori
Primo
Writing – Review & Editing
;Angela AmbrosoneMembro del Collaboration Group
;Leonardo CristofaniMembro del Collaboration Group
;Francesco FattappostaSupervision
;Antonio CurràUltimo
Writing – Review & Editing
2022
Abstract
Immune checkpoint inhibitors (ICIs) have shown promise in treating cancer patients and Pembrolizumab is a monoclonal IgG4 antibody that targets a human cell surface protein (receptor) called PD-1. Among the side effects a rare cranial nerve palsy unrelated to the surgical treatment may occur. We report a case of a woman, which after neurosurgical treatment for cerebellar metastasis presented painless third cranial nerve palsy. Informed consent was obtained from the patient for the publication of this report.| File | Dimensione | Formato | |
|---|---|---|---|
|
Missori_Third Cranial Nerve Palsy_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
378.21 kB
Formato
Adobe PDF
|
378.21 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
